drugset / Trial / NCT07468071
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.
Timeline
- Start
- 2026-06-08
- Primary completion
- 2029-06-15
- Completion
- 2029-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BATOPROTAFIB | Small molecule | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Opnurasib | Small molecule | — | — |
| Subject | Tislelizumab | Monoclonal antibody | — | — |
| Subject | Trametinib | Small molecule | — | — |
Indications
No indication recorded.